Riskpilot← Back to searchSign inGet full accessREPOCEUTICALS A/S
A/SActiveCVR 36494433Slotsmarken 12, 1. thManufacture of pharmaceutical preparations · NACE 2120Est. 20152 employees
Revenue 2024
DKK 0
EBITDA margin
—
+7% vs 2023
Equity ratio
39.7%
Financial strength
Net profit 2024
DKK -6,3M
-21% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -5,1M | +7% |
| Net profit | DKK -6,3M | -21% |
| Total assets | DKK 12,1M | +24% |
| Equity | DKK 4,8M | +69% |
| Employees | 2 | — |
Legal name
REPOCEUTICALS A/S
CVR number
36494433
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
16. januar 2015
Share capital
DKK 896.135
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og formanden for
bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle repositionerede lægemidler samt dermed beslægtede aktiviteter
Address
Slotsmarken 12, 1. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | -75 | -0 | -0 | -0 | -0 |
| EBITDA | -1.201 | -5.459 | -4.975 | -5.469 | -5.084 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.201 | -5.459 | -4.975 | -5.469 | -5.084 |
| Net financials | -122 | -379 | -67 | -425 | -1.654 |
| Profit before tax | -1.323 | -5.838 | -5.042 | -5.894 | -6.738 |
| Tax | -464 | -1.435 | -1.213 | -694 | -463 |
| Net profit | -859 | -4.402 | -3.829 | -5.200 | -6.275 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9.885 | 14.335 | 9.491 | 9.686 | 12.056 |
| Equity | 5.183 | 12.041 | 8.300 | 2.838 | 4.792 |
| Long-term debt | 0 | -453 | 186 | 5.499 | 1.702 |
| Short-term debt | 3.211 | 1.516 | 1.005 | 1.349 | 5.562 |
| Total debt | 3.211 | 1.063 | 1.190 | 6.848 | 7.264 |
EBITDA margin
-508362800.0%
This company
15.8%
Market median
-3217486176% vs market
20202024
Equity ratio
39.7%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
-130.9%
This company
18.4%
Market median
-811% vs market
20202024
Net profit margin
-627454800.0%
This company
8.1%
Market median
-7746355656% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.52×
This company
0.62×
Market median
-145% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB Management | Management | 2016 |
| Former (1) | ||
HL Management | Management | 2015 – 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Board of Directors | 2019 – 2025 | |
| Board of Directors | 2019 – 2023 | |
| Chairman | 2019 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 15–19.99% | 15–19.99% | 2025 | |
| Company | 10–14.99% | 10–14.99% | 2021 | |
| Company | 10–14.99% | 10–14.99% | 2021 | |
| Company | 10–14.99% | 10–14.99% | 2019 | |
| Company | 5–9.99% | 5–9.99% | 2020 | |
| Company | 5–9.99% | 5–9.99% | 2016 | |
| Company | 5–9.99% | 5–9.99% | 2019 | |
| Company | 25–33.32% | 25–33.32% | 2015 | |
| Company | 10–14.99% | 10–14.99% | 2016 | |
| Company | 15–19.99% | 15–19.99% | 2015 | |
| Company | 5–9.99% | 5–9.99% | 2015 | |
| Company | 10–14.99% | 10–14.99% | 2018 | |
| Individual | 20–24.99% | 20–24.99% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2016 | |
| Individual | 25–33.32% | 25–33.32% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2018 | |
| Company | 5–9.99% | 5–9.99% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NIELS ERIK JESPERSEN HOLDING ApS
REPOCEUTICALS A/S Board members of REPOCEUTICALS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torsten Bjørn | Management | 0 companies |
| Henrik Lasse Lindblad | Management | 0 companies |
| Henrik Bulskov | Chairman | 0 companies |
| Preben Møllegaard Grundtvig | Board of Directors | 0 companies |
| Christian Vinding Thomsen | Board of Directors | 0 companies |
| Charlotte Pahl | Board of Directors | 0 companies |
| Nete Søgaard Poulsen | Board of Directors | 0 companies |
| Troels Peter Troelsen | Board of Directors | 0 companies |
| Sigbjørn Georg Nielsen Kjærgård | Chairman | 0 companies |